Human erythrocyte insulin receptor processing is affected by the oxidizing agent menadione.
Insulin-induced down-regulation of erythrocyte insulin receptors is a simplified model that can provide useful information on the cell surface regulative phenomena and on role of the plasma membrane and cytoskeleton in such physiological processes. Oxidative imbalance was examined since it was shown to play an important role in numerous cellular pathologies as well as in cell aging. Specifically, the free radical inducer menadione was used in order to evaluate if this compound is able to modify (and in which manner) the down-regulation process. Biochemical, biophysical, and ultrastructural approaches were used. The results obtained seem to indicate that menadione-induced oxidative damage was able to decrease the insulin-induced down-regulation process, as measured by binding assays. This effect was accompanied by slight alterations in plasma membrane ultrastructure and insignificant variations in plasma membrane lipid composition. In addition, the decrease in membrane order, measured by electron paramagnetic resonance, which was shown to usually occur during the process of down-regulation, was not observed. In contrast, cytoskeletal protein assembly, as previously shown in other in vitro systems, appeared to be remarkably altered. Such changes in specific cytoskeletal elements could lead to the decrease of down-regulation phenomenon induced by menadione. Changes in electrophoretic pattern of some cytoskeletal proteins (e.g., spectrin) reinforce this hypothesis. Considering the importance of free radicals in cell injury, data reported here could represent a specific example of a general mechanism by which cell surface receptor expression and recycling can be modified by changes in some intracellular molecule redox status and cell ionic homeostasis.
Department of Ultrastructures, Istituto Superiore di Sanitá, Roma, Italy.
W
W
Malorni
R
R
Masella
M T
MT
Santini
F
F
Iosi
P
P
Samoggia
A
A
Cantafora
D
D
Merrell
S W
SW
Peterson
D008841:Actin Cytoskeleton / Q000187:drug effects / Q000648:ultrastructure; D002478:Cells, Cultured; D003599:Cytoskeleton / Q000187:drug effects / Q000648:ultrastructure; D015536:Down-Regulation / Q000187:drug effects; D004578:Electron Spin Resonance Spectroscopy; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D005455:Fluorescent Antibody Technique; D005614:Freeze Fracturing; D006801:Humans; D007328:Insulin / Q000097:blood / Q000494:pharmacology*; D007700:Kinetics; D008855:Microscopy, Electron, Scanning; D011972:Receptor, Insulin / Q000187:drug effects / Q000378:metabolism*; D014812:Vitamin K / Q000494:pharmacology*
D007328:Insulin; D014812:Vitamin K; D011972:Receptor, Insulin